What Are the Purported Benefits of Tirzepatide (30 mg)?
Tirzepatide is a synthetic 39-amino acid peptide linked to a C20 fatty acid, designed to activate two metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It binds the GIP receptor with an affinity comparable to that of native GIP and binds the GLP-1 receptor with lower affinity, creating a signaling profile that favors GIP activity.
In preclinical research, this tirzepatide peptide is used to investigate how dual activation of the incretin receptors affects glucose control, insulin and glucagon signaling, gastric motility, and satiety pathways under controlled laboratory conditions.
Tirzepatide serves as a research tool to examine how multiple receptor pathways interact in metabolic regulation. The fatty acid modification improves stability and extends peptide persistence in experimental systems. Research focuses on understanding how combined GIP and GLP-1 receptor activation influences insulin secretion, glucagon suppression, and energy balance. All findings remain investigational and are presented strictly for research use, without clinical or therapeutic claims.
What Is the Chemical Makeup of Tirzepatide (30 mg)?
Tirzepatide’s sequence includes two aminoisobutyric acid (Aib) residues, which slow enzymatic breakdown and improve stability. The peptide begins with tyrosine at the N-terminus and ends with an amidated C-terminus, both of which support structural integrity.
A C20 fatty acid (icosanedioic acid) is attached through a linker at lysine 20. This modification increases albumin binding and extends the peptide’s plasma half-life to about five days (116.7 hours) in experimental models.
- Peptide length: 39 amino acids
- Molecular weight: 4813.48 g/mol
- Chemical formula: C₂₂₅H₃₄₈N₄₈O₆₈
- CAS: 2023788-19-2
- Synonyms: P1206, LY3298176, tirzepatida, tirzepatidum, OYN3CCI6QE
- Peptide sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Researchers who buy tirzepatide peptide often choose the 30 mg format for laboratory studies that require repeated testing or comparative analysis.
What Does Scientific Research Say About Tirzepatide (30 mg)?
Scientific research on Tirzepatide centers on its role as a dual incretin receptor agonist and on how its structure affects receptor binding and signaling strength. Preclinical studies examine how combined activation of GIP and GLP-1 receptors influences insulin secretion, glucagon secretion, gastric emptying, appetite signaling, and energy expenditure.
These investigations rely on receptor-binding assays, cell-based signaling studies, and glucose regulation models to compare dual agonism with single-receptor GLP-1 agonists.
Research Applications
- Receptor binding studies: Measuring how strongly Tirzepatide binds to GIP and GLP-1 receptors and how long receptor activation is maintained
- Cell signaling assays: Assessing cAMP and related signaling responses in cells expressing incretin receptors
- Glucose regulation models: Evaluating insulin and glucagon responses in pancreatic tissue and animal models
- Metabolic response studies: Examining changes in body weight, energy use, and glucose handling across tissues
- Comparative studies: Comparing dual GIP/GLP-1 agonism with GLP-1-only compounds, such as semaglutide
Pathway and Mechanistic Context
- GIP receptor signaling: Activates cAMP pathways involved in insulin secretion, glucagon modulation, gastric activity, and satiety signaling
- GLP-1 receptor signaling: Activates similar pathways that support glucose-dependent insulin release and appetite regulation
- Dual agonism: Combined receptor activation produces complementary metabolic effects in preclinical systems
- Imbalanced signaling: Stronger GIP activity and weaker GLP-1 activity distinguish Tirzepatide from GLP-1-dominant agonists
- Fatty acid conjugation: Enhances albumin binding and reduces clearance, supporting sustained receptor engagement in research models
All findings are model-dependent and context-specific. Tirzepatide is supplied for controlled laboratory and preclinical research to support mechanistic studies, structure–activity analysis, and evaluation of dual GIP and GLP-1 receptor agonism.
What Are the Storage Conditions for Tirzepatide (30 mg)?
Unreconstituted (lyophilized) tirzepatide is commonly stored at <=-20 °C for long-term stability, protected from light and moisture, and transferred promptly to the recommended temperature upon receipt to help maintain peptide integrity for receptor-signaling assays.
After reconstitution in an appropriate diluent (e.g., sterile water, PBS, Tris buffer, or assay-specific buffer), solutions are typically stored at 2–8 °C and used within 24–48 hours in accordance with laboratory best practices. Avoid repeated freeze–thaw cycles; for longer workflows, aliquot reconstituted solutions and store at <=-20 °C while documenting freeze–thaw events to monitor potential loss of activity.
Are you looking to buy Tirzepatide (30 mg) online?
If you’re looking to order Tirzepatide (30 mg) online at wholesale prices, contact Medical Spa RX for guidance on how to do so.
This product is supplied strictly for laboratory research use only and is not approved for human or veterinary administration. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines. By purchasing or using this material, the buyer confirms that they are a qualified researcher and that the product will be used exclusively in controlled research settings compliant with all applicable regulations.
Sources
https://www.pnas.org/doi/10.1073/pnas.2116506119
https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179
https://pmc.ncbi.nlm.nih.gov/articles/PMC9149770/https://pmc.ncbi.nlm.nih.gov/articles/PMC9396640/